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Thalidomide and the Titanic:
Reconstmcting the Technology Tragedies
of the Twentieth Century
George J. Atmas, JD, MPH, anil Shermati Elias. MD
Tlie Titanic lias become a mct^hor
for the disastrous consequences of an
unqualified belief in the safety and
invincibility of new technology. Simi-
larly, the thalidomide tragedy stands for
all of the "monsters" tliat can be inadver-
tently or negligently created by modem
medicibnc. TTialidomlde, once banned,
has rcttimed to the center of controversy
with tlie Food and Drug Administra-
tion s (FDA's) announcement that
thalidomide will be placed on the market
for the treatment of erythema nodosum
lejHosum. a severe demiatological com-
plication of Hansen's disease. Although
this indication is very restricted, thalido-
mide vvill be available for off-label uses
once it is on the market
New laws regarding abortion and a
new technology, ultrasotind, make rea-
sonable the approval of thalidomide for
patients who suffer from serious condi-
tions it can alleviate. In addition, the
FDA and the manufacturer have pro-
posed the most stringent postmarkedng
monitoring ever used for a prescription
drug, including counseling, contracep-
tion, and ultrasonography in the event
of pregnancy.
The 77/fln/c/thalidomide lesson
for the FDA and public health is that
rules and guidelines alone are not suf-
ficient to guarantee safety. Continuous
vigilance will be required to ensure
thai all reasonable postmarketing mon-
itoring steps are actually taken to avoid
predictable and preventable teratogenic
disasters. iAm J Public Health. 1999;
89:98-101)
At the close of the 20th century, there
seems to be a longing to make some sense of
the century's tnost celebrated technological
tragedies. The tragedies of the Tttanic and
tlialidomide rank at or near the top in our pro-
progress culture's consciousness of techno-
logical disasters. Each has had a much wider
impaet on the world than is reflected in the
loss of lite and limb, and each has eome to
stand for disaster caused by a combination of
greed and overconfidence in teclinology.
The Titanic, of course, has become a
metaphor for the disastrous consequences of
an unqualified belief in the safety and invinci-
bility of new technology.' Altliough only 1500
people lost their lives when the ship went
down, it was tlie toUil surprise tlie world felt at
the sinking of tliis "tinsinkable" ship tliat pre-
saged tlie collapse of the old order of British
invincibility and technological superiority.
The Tttatiic probably was the safest passenger
ship of its time, but human mistakes and over-
reliance on technology magnified tlie loss of
life when the ship sank. Survivor Lawrence
Beesley noted, refleeting on the tragedy and
how similar tragedies might be avoided in the
futtire, "The range of the wireless apparatus
might be extended, but the principal defect is
the lack of an operator for night duty on some
ships. The awful fact that tlie California lay a
few miles away, able to save every soul on
board, and could not catch the message
because the operator was asleep, seems too
cruel to dwell upon."" The Titanic has, of
course, been symbolically raised at century's
end by its celebration in the most commer-
cially successful film in history, Tttanic. in
which the story of the ship's sinking is recon-
structed for our teclinological age. Even when
the story is reconstructed with a "love con-
quers all" theme, we remain fascinated with
tlie idea that nature, whether in the fonn of an
iceberg, a tomado, a volcano, or an asteroid,
can cause harm uncontrollable by technology.
Tlie thalidomide tragedy of midcentury
is much more recent than the Tttanic tragedy,
but it ah^eady stands for all of the deformities
and "monsters" that can be inadvertently or
negligently created by modem medicine. '̂̂
Thalidomide's hann cannot be totally con-
trolled. Nonetheless, through a combination
of careful medical postmarketing monitoring
and new laws, today thalidomide can be
thought of as doing more good than harm.
Thalidomide also holds wider postmarketing
lessons for all drugs that carry potentially
devastating dangers.
Thalidomide as Teratogen
The popular medical belief that the
human fetus was protected from maternal
drug exposures in the sanctum sanctonitn of
the uterus^ was shattered in 1961 when Lenz
in Germany and McBride^ in Australia inde-
pendently suggested that prenatal exposure to
thalidomide was the cause of serious birth
defects. These abnormalities came to be
known as thalidomide embryopathy, which
includes amelia or phocomelia, cranial nerve
palsies, microtia, choanal atresia, congenital
heart defects (e.g., ductus, conotruncal
defects), bowel atresias, gallbladder aplasia,
and urogenital abnormalities.** Thalidomide
was first introduced in Gemiany in 1958 as
an anticonvulsive agent but was soon found
unsuitable for this indication. Nonetheless,
clinicians recognized that this drug was
useful for a variety of other ailments, includ-
ing moming sickness caused by pregnancy,
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hypertension, nnd migraines." In tlie United
States. Richardson-Mem 11 hoped ultimately
to have thalidomide approved as an over-tiic-
couiiter drug and planned to recommend it as
treatment for myriad problems including
alcoholism, anorexia, astlima. cancer, poor
schoolwork. prcmatutx: ejaculation, psychas-
tlienia. and tubcfculosis."*
By 1961. thalidomide was widely pre-
scribed in Europe. Pregnant women in 48
eountries took thalidomide. resulting in the
live birtlis of more tlian 8000 aftected infants."*
Of infante exposed be^veen days 35 and 48
after tlie last menstrual period. 20% to 30%
had severe limb defects and other organ
defecte.'"" In the United States, tlie drug had
foiled to receive Food and Drug Administra-
tion (FDA) approval, not because of potential
teratogenicity but beeause of concems about
peripheral neuropatliy."* Even tliough Richaid-
son-Menill distributed tnore than 2.5 million
thalidomide tablets to 1267 physicians who
gave them to some 20 000 patients in "clinical
trials." only 17 affected infants were reported
in the United States."* Once tlialidornide was
withdrawn from the market worldwide,
affected infants continued to be bom up to
about May 1963 and very exceptionally
beyond this date."*̂  Tlie drug's legalization in
Brazil and use in South America, may, how-
ever, have resulted in at least 34 cases of
thalidomide embryopathy since 1965.'" The
next chapter in history's most notorious
human teratogen is about to be written.
New Indications for
Thalidomide
Thalidomide has returned to the center
of an emotionally charged controversy. On
July 16. 1998. the FDA cleared thalidomide
for marketing by a New Jersey-based phar-
maceutical company. Celgene. inc. for ery-
thema nodosum leprosum, a severe dermato-
logical complication of Hansen's disease
(formerly known as leprosy).'•* Hansen's dis-
ease affects about 7000 people in the United
States, and approximately 50 of them are
affected by erythema nodosum leprosum.
The FDA has announeed that thalidomide
will be among the most tightly restricted
drugs ever to be marketed in the United
States.'** The drug policy question is how
striet these postmarketing approval controls
should be.
Celgene, in cooperation with the FDA,
has developed the System for Thalidomide
Edueation and Preseribing Safety (STEPS)
program. This program includes mandatory
registration of all physicians who prescribe
the medication and all patients who take it,
as well as mandatory contraceptive measures
for both males and females.'•* Women wlio
take thalidomide miisl liiive a negative preg-
nancy test tcsult. show proof thai they luo
using 2 fonns of contraception, and submit
to monthly pregnatiey tests (weekly in the
lii-st month)." Drawings ordefonncd infants
must appear on eveiy package of the drug.
Both the patient and the physician must sign
a document signifying tliat tlie patient under-
stands the risks and is using contracep-
tion.''•'"* Prescriptions are limited to a 1-
month supply. Whether thalidomide use in
males affects spenn or fetal development is
unknown, but males taking the dmg will be
counseled to use condoms when having
intercourse with women of childbearing
age.'"* Thalidomide causes not only birth
defects but also peripheral neuropathy, and
patients must be monitored to determine
"how dose and use of tlie drug affects onset
of this side effect and irreversibility."'"'These
controls put thalidomide among the most
stringently regulated drugs in the United
States, but tliis may not be saying much.
Although thalidomide would be mar-
keted for use in erythema nodosum lepro-
sum. physicians would be able to prescribe it
for so-called off-label uses (i.e., for other
than erythema nodosum leprosum). For
example., thalidomide has been shown to be
effective in the treatment of oral aphthous
ulcers of the mouth and oropharynx in
patients with HIV infection,'^ Such ulcers
can be extensive and debilitating, and
thalidomide appears effective for pain relief
and allows patients to eat and in some cases
avoid a cachectic death. More than half of
the patients with these ulcers are completely
healed by 4 weeks of drug therapy, and
almost 90% are at least partially healed.'^
Indeed, thalidomide appears to be so suc-
cessful in oral aphthous ulcer treatment that
within the last few years buyer's clubs have
been purchasing the drug in Brazil, where it
is legally available, and distributing it ille-
gally to AIDS patients in the United States.
Just as in the early 1960s, claims have also
been made for the beneficial effeets of
thalidomide in many conditions, including
macular degeneration, rheumatoid arthritis,
diabetes mellitxis, graft-vs-host disease fol-
lowing bone marrow transplants, autoim-
mune diseases, and sotne cancers. Thus, the
off-label use of thalidomide may inevitably
lead to exposure of many fetuses.
Risk-Benefit Analysis
Did the FDA properiy weigh the risks
and benefits of introducing thalidomide to
the US market? The major risk is the
inevitable tragedy that infants will again be
born with the thalidomide embryopafhy,
Extensive regulations will be hclpllii but do
not guarantee prevention of such births. The
closest analogy is Acculanc, an antiacne
medication that can also cause severe birth
defects.'" The FDA tightly regulates its use.
Nonetheless, up to 8 infants with isotretinoin-
related malfomiations are bom each year in
the United States (A, A. Mitchell, oral com-
munication, April 29, 1998/
Since the 1960s, a legal change and a
technological development—Roe v Wade
and ultrasonography—have made thalido-
mide a "different" drug today. These 2
changes make it reasonable to treat thalido-
mide in a similar way to the other approxi-
mately 30 drugs that carry a serious risk to the
fetus." Since 1973 and the US Supreme
Court's decision in Roe v Wade., American
woman have had a constitutional right to ter-
minate tlieir pregnancies prior to fetal viabil-
ity. At the time that thalidotnide failed to
obtain FDA approval in the United States,
abortion, with a few exceptions, was a crime.
The thalidomide tragedy itself had a direct
role in helping to change the public's attitude
toward abortion. In late 1962, Sherd Chessen
Finkbine read a newspaper article linking
thalidomide to birth defects and later discov-
ered tliat the "headache pills" her husband had
obtained on a trip to England contained
thalidomide."* Unable to have an abortion in
Arizona, she ultimately flew to Sweden for
the abortion of what turned out to be an
affected fetus. Her story was widely publi-
cized, and a Gallup poll conducted soon there-
after showed that 52% of Americans thought
she had done tlie right tiling."^ Also, the major
potential effect of thalidomide on the fetus is
limb deformity, which can now be observed
relatively early in pregnancy by ultrasound, a
technology not available in the 1960s.
Any reasonable attempt to prevent the
birth of infants with physical disabilities
requires counseling patients who are taking
thalidomide not to become pregnant and urg-
ing those in whom contraception fails either
to discontinue the drug or to agree to have
their fetuses evaluated for severe structural
anomalies by high-resolution ultrasonogra-
phy. Most major fetal malfonnations can be
detected by ultrasonography, at least by 18 to
20 weeks" gestation. The final abortion deei-
sion. nonetheless, tnust be the woman's.
Women, tiot the government, their employ-
ers, or their physicians, must make the final
decisions about continuing or not continuing
their pregnancies.'"*
The most compelling benefit of FDA
approval of thalidomide is that it makes
thalidomide available to patients who have
conditions it can ullcviute. in crises in which
the suffering is great, no reasonable medical
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;iltcnwlt\c.s atv luailaMc. luul thalidoinidc is
ctllvtivc, (lie i n . \ is i-onxvl lo ^.'onclndc thai
Its tcnUoj;cntcH> .ilonc slunild nol pivcltidc
ils use, Wotucn should tiol be dotiicd ctTcc-
ti\c lhi,'t~,ip\ lor scNCtv cxisiini; disease solely
Ixvausc the tliet;ipy poses potcnhally seven:
risks to ihcir fetuses. Because oflhalldo-
mido's teratoi:eniciiy, however, physicians
hiue a respotisibihly tiol to pteseribe il in
fertile women uttless no reasonable medical
alteniatiN e exists, ihe eotidition beitig treated
IS senous. reliable cotitraceptioti is used, atid
the woman is fully itilonnoti oT ihe dntg's
risks ;md benefits. The Atnerican College of
Obstotrieians and Gynecologists (ACOG)
also concluded tluit neither Uialidomide nor
any drug should be prevented from being
introduced or withdrawn from the market
solely beeause it is teraiogcnic. Instead.
ACOG smmgly supports eftorts lo prevent
exposure to known teratogenic agents in
women w ho are pregnant or eontemplating
pregnane\.""
Thalidomide's resurrection provides an
opportunity to determine whether sotne
drugs are potentially so dangerous that tlieir
use shottid be restricted to tlie conditions for
which tlie drug is FD.\ appro\ ed. So far tliis
opportunity has been missed, but Uie birtli of
even one affected infant from off-label use
will undoubtedly provoke this debate. As
long as off-label uses arc pennitted. the FDA
should insist not only that prescriptions for
such uses be subject to the FDA's safeguards
for approved uses but also that patients be
infomied that thalidomidc has not been
approved for the off-labcl use contctnplated.
.approval of thalidomide is consistent
with otlier FDA drug approvals. Many valu-
able drugs have potential teratogenicity,
including warfarin, litliium. angiotensin<on-
verting enzyme inhibitors, nonsteroidal antiin-
flammatory drugs, aminoglycosides.
immunosuppressants. and antineoplastic
drugs.' ' Even the Thalidomide Victims
Association of Canada agreed to help Celgene
obtain FDA approval for thalidomide. so long
as steps arc taken to fully inform physicians
and patients and to try to prevent harm to
fetuses. The organization successfully resisted
thalidomide's being given a totally new name
(Cclgenc wanted to call il Synovir. it will be
marketed as TTialomid) and got the labeling
changed from "Avoid pregnancy" to "Do nol
get pregnant."''
Learning* From Tragedies
Not all tragedies can be redeemed, but
we can leam from all tragedies. The FDA has
tbe responsibiltty to ensure that thalidomidc is
5afely introduced in the United States. But
physicians and their patients must share
rcspoiisihility lor ils proper use. Only if
cvetyune meels ihesc tesponsibilitics is tlietx;
a renlislic oppoiitmity to obiaiti the bencfit.s of
thaliilnmiiie and lo minimi/e the risks by prc-
vetUing birth lielects, The FDA, for example,
has leeenlly heett sevetely criticized for its
petfonnaiice iti posltnarketitig monitoring of
dmg safety.""' As more and tnore powerful
drugs are approved for marketing, il has
becotiic appatetit that much more careful
pnstmarketiitg moiiiloring is needed than has
been loleraled lo date. In the absence of care-
ful iiioniioritig. many powerful diitgs—such
as the new diabetes drug troglitazone, which
eiin cause severe liver toxicity—would have
lo be banned as unsafe,"'' Physicians have a
central role in posttnarkcting monitoring and
should prescribe thalidomide only af̂ er deter-
mining that it is the best drug for a serious
condition and counseling fertile women
palienls lo avoid pregnancy. And fertile
women should take all reasonable steps to
avoid pregnancy while taking thalidomide.
The Titanic can be reconstructed as
myth but not raised intact (it is in 2 pieces).
Tlialidomide, because of changes in both law
and tiiedical technology, can be raised from
its mythical rnonstcr drug status and reintro-
duced as a therapeutic component of modem
medicine. Like preventing death at sea. pre-
venting thalidotnide-affected births will
require not only medical technology but also
human alertness. The decision to use thalido-
tiiide should be based on a realistic assess-
ment of risks and benefits, as well as specific
FDA. physician, and patient action to mini-
mize predictable harm to fetuses.
The major lesson that tlie Titanic disas-
ter holds regarding ihalidomide is tliat wrap-
ping a tragedy in the myth of a love story can
obscure its horror and transfonn a tragic les-
son into entertainment. FDA approval of
thalidomide itself comes packaged as a
mythical, although somewhat more complex,
love story. Randy Warren, an affected child
of a mother who took the drug, has dramati-
cally argued in support of FDA approval:
"Our hearts tell us this [thalidomide] did hor-
rible things to our mothers and to ourselves,
but our heads tell us 'How can we deny it to
people who are suffering?'"'' The myth, of
course, is that society and the FDA have ever
cared deeply about the suffering of people
with ilansen's disease, when historically the
United States has isolated "lepers" in "leper
colonies" and left them to fend for them-
selves with the help of private charity.'"^ Sim-
ilarly, women with AIDS in the United
States were denied zidovudine for years
because ofthe fear that it was teratogenic.
Society is perfectly capable of being
indifTercnt to human suffering and would
continue to be in this instance if a private
corporation, Cclgenc, had not thought it
could profit frotn manufacturing and selling
thalidomide. Ignoring commercial and profit
motives here could lead to complacency in
tnotiitoring and result in the same type of
disaster as the sinking of the Titanic. The
Titanic's owners reduced the number of
lifeboats to save tnoney, and the crew was
unfatniliar with their operation. ' The
77ra/i/c/thalidomide lesson for the FDA and
public health is that continuous vigilance is
required to ensure that all reasonable steps
are taken to avoid predictable and pre-
ventable disasters. For the safety ofthe pub-
lic's health, this broad lesson should be
applied by the FDA, physicians, and drug
cotnpanies to require rigorous postmarket-
ing monitoring of all new and potentially
dangerous drugs. D
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